Healthcare Industry News: immunotherapy
News Release - October 29, 2015
Bellicum Appoints Alan K. Smith as Senior Vice President of ManufacturingHOUSTON--(Healthcare Sales & Marketing Network)--Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies, today announced the appointment of Alan K. Smith, Ph.D., as Senior Vice President of Manufacturing.
“We are pleased to welcome an executive with Alan’s level of expertise in the cellular immunotherapy field,” said Tom Farrell, Bellicum’s President and Chief Executive Officer. “His experience in clinical process and systems development, and cGMP manufacturing and quality, will be instrumental in helping us to advance our pipeline of cellular immunotherapies for cancers and orphan inherited blood disorders.”
Dr. Smith joins the Company with over 30 years of experience in cellular therapeutics, during which time he served in various leadership roles in Research and Development, Manufacturing and Quality. Most recently, he was Vice President of Research & Development and Cellular Therapeutics at LifeNet Health, an organ procurement organization and tissue bank, and its wholly owned subsidiary, The Institute of Regenerative Medicine, a global research center focused on innovations in cellular therapies and tissue engineering.
Previously, Dr. Smith served as a consultant to the cell therapy industry, contributing to over 25 successful FDA regulatory submissions for cell therapy products and devices. He also served as President and Chief Executive Officer of Cognate BioServices, Inc., a contract service provider performing R&D and contract manufacturing for clients developing cellular therapies in regenerative medicine for cancer, immunotherapy, cardiovascular and neurological applications. Previously, he was the Chief Operating Officer and Senior Vice President of Research & Development at Osiris Therapeutics, where he created clinical processes and systems to deliver cell and gene therapies for hematopoietic, cardiovascular, immunotherapy and orthopedic applications. Earlier in his career, Dr. Smith led R&D functions for Aastrom Biosciences, Inc. (now Vericel Corporation), Geneic Sciences, Inc. and Baxter Healthcare Corporation, immunotherapy Division.
Dr. Smith is an Adjunct Professor in the Department of Biology and Molecular Cell Biology at Eastern Virginia Medical School and has previously held adjunct professorships at California State University Long Beach and Utah State University. Dr. Smith earned his Bachelor of Science in Chemistry at Southern Utah State College and his doctorate in Biochemistry at Utah State University.
About Bellicum Pharmaceuticals
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company is using its proprietary Chemical Induction of Dimerization, or CID, technology platform to engineer and control components of the immune system in real time. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), and CAR T and TCR cell therapies. More information can be found at www.bellicum.com.
Source: Bellicum Pharmaceuticals
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.